blood

Interferon-? Activates Multiple STAT Proteins and Upregulates Proliferation-Associated *IL-2R?, c-myc,* and *pim-1* Genes in Human T Cells

Sampsa Matikainen, Timo Sareneva, Tapani Ronni, Anne Lehtonen, Päivi J. Koskinen and Ilkka Julkunen

---

Updated information and services can be found at:

http://bloodjournal.hematologylibrary.org/content/93/6/1980.full.html

Articles on similar topics can be found in the following Blood collections

Immunobiology (4477 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:

http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

IMMUNOBIOLOGY

Interferon-α Activates Multiple STAT Proteins and Upregulates Proliferation-Associated *IL-2Rα*, *c-myc*, and *pim-1* Genes in Human T Cells

By Sampsa Matikainen, Timo Sareneva, Tapani Ronni, Anne Lehtonen, Päivi J. Koskinen, and Ilkka Julkunen

Interferon-α (IFN-α) is a pleiotropic cytokine that has antiviral, antiproliferative, and immunoregulatory functions. There is increasing evidence that IFN-α has an important role in T-cell biology. We have analyzed the expression of *IL-2Rα*, *c-myc,* and *pim-1* genes in anti-CD3–activated human T lymphocytes. The induction of these genes is associated with interleukin-2 (IL-2)–induced T-cell proliferation. Treatment of T lymphocytes with IFN-α, IL-2, IL-12, and IL-15 upregulated *IL-2Rα*, *c-myc,* and *pim-1* gene expression. IFN-α also sensitized T cells to IL-2–induced proliferation, further suggesting that IFN-α may be involved in the regulation of T-cell mitogenesis. When we analyzed the nature of STAT proteins capable of binding to *IL-2Rα*, *pim-1*, and *IRF-1* GAS elements after cytokine stimulation, we observed IFN-α–induced binding of STAT1, STAT3, and STAT4, but not STAT5 to all of these elements. Yet, IFN-α was able to activate binding of STAT5 to the high-affinity *IFP53* GAS site. IFN-α enhanced tyrosine phosphorylation of STAT1, STAT3, STAT4, STAT5a, and STAT5b. IL-12 induced STAT4 and IL-2 and IL-15 induced STAT5 binding to the GAS elements. Taken together, our results suggest that IFN-α, IL-2, IL-12, and IL-15 have overlapping activities on human T cells. These findings thus emphasize the importance of IFN-α as a T-cell regulatory cytokine.

© *1999 by The American Society of Hematology.*

INTERFERON-α (IFN-α) has antiviral, antiproliferative, and immunomodulatory functions.[1-3] IFN-α is produced in the course of immune response, especially during viral infections. Macrophages and other antigen-presenting cells are the main cellular sources of IFN-α. Immunomodulatory functions of IFN-α include the enhancement of natural killer (NK) cell and T-cell cytotoxicity,[2,3] and knockout mice lacking a functional type I IFN receptor were unable to generate a cytotoxic T-lymphocyte response to lymphocytic choriomeningitis virus.[4] IFN-α has been shown to promote Th1-type immune responses, eg, by inducing interleukin-12 (IL-12) receptor β2 chain and IFN-γ gene expression in human T cells.[5-7]

IL-2 is the major growth factor for T lymphocytes. IL-2 stimulation of T cells is associated with the activation of several signaling pathways, including the Janus tyrosine kinase-signal transducer and activator of transcription (Jak-STAT) pathway.[8-11] Binding of IL-2 to its receptor activates Jak1 and Jak3 tyrosine kinases, leading to tyrosine phosphorylation, dimerization, and nuclear translocation of STAT5 proteins. The role of STAT5 in IL-2–induced T-cell proliferation is controversial,[12,13] but recent studies with STAT5a-deficient mice suggest that STAT5a is involved in T-cell proliferation. Splenocytes from STAT5a-deficient mice show decreased proliferative response to IL-2, a result of impaired expression of IL-2 receptor α (IL-2Rα) chain.[14]

IL-2 signals via a specific receptor, the high-affinity form of which is composed of three subunits, α (CD25), β (CD122), and γ (γ_common) chains. Whereas the β and γ chains are constitutively expressed in resting T lymphocytes, the α chain is expressed only in activated T lymphocytes.[15] Both T-cell receptor stimulation and IL-2 treatment are able to induce α chain gene expression. IL-2Rα chain is required for the high-affinity binding of IL-2 and it is essential for optimal proliferative responses of the mature T cells.[14,15] A human immune disorder, characterized by decreased numbers of peripheral T cells, arises from a mutation in the gene coding for the IL-2Rα chain.[16]

IL-2–induced T-cell proliferation is associated with the induction of several IL-2–responsive genes, such as *c-myc* and *pim-1*.[15,17] The *c-myc* gene is expressed in a wide variety of proliferating cells, and it is activated in many types of human and animal neoplasia, including leukemias and lymphomas.[18] The *pim-1* gene encodes a serine/threonine kinase that is expressed predominantly in hematopoietic cells.[19,20] Studies with transgenic mice have demonstrated that *pim-1* can also act as an oncogene in synergy with *c-myc, N-myc,* or *bcl-2* to induce B- and T-cell lymphomas.[21-23] In addition, there is evidence that overexpression of *pim-1* can accelerate lymphoid and myeloid cell proliferation by enhancing cell survival.[24-26] Both c-Myc and Pim-1 proteins may thus have important roles in mediating cytokine-induced mitogenic signals.

Although IFN-α is an important T-cell regulatory cytokine, most studies so far regarding IFN-α signaling and gene activation have been performed using nonlymphoid cells. In this report, we have studied the cytokine-dependent gene expression in anti-CD3–activated human T lymphocytes focusing on genes that are involved in T-cell mitogenesis. We show that, in addition to IFN-α, also IL-2, IL-12, and IL-15 induce *IL-2Rα*, *c-myc,* and *pim-1* gene expression. We also show that IFN-α induces tyrosine phosphorylation of STAT1, STAT3, STAT4, STAT5a, and STAT5b and enhances their binding to the IFN-γ activated sequence (GAS) elements of the IFN-α–responsive genes.

MATERIALS AND METHODS

T-cell culture. Leukocyte-rich buffy coats were obtained from healthy blood donors (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland). Mononuclear cells were isolated by density gradient centrifugation using Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden). Monocytes were removed by adherence, and T cells were further purified by nylon wool columns. Purified T cells were activated with a 1:1,000 dilution of anti-CD3 monoclonal antibodies containing ascites fluid (kindly provided by Dr Matti Kaartinen, University of Helsinki, Helsinki, Finland) and cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS; Integro, Zaandam, The Netherlands) and 100 IU/mL IL-2 for 5 to 6 days. T cells were further expanded for 3 to 5 days with RPMI supplemented with IL-2. As determined by flow cytometry, more than 99% of cells were CD3$^+$, consisting of CD4$^+$ (30%) and CD8$^+$ (70%) cells (data not shown). In all experiments, T cells were removed from IL-2–containing medium 12 to 16 hours before cytokine stimulation. In each experiment, T cells from two to four donors were used.

Cytokines. Highly purified human leukocyte IFN-α (13 × 10^6 IU/mL) was provided by Dr Hannele Tölö (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland). IFN-β (0.2 × 10^6 IU/mL) was from Bioferon GmbH & Co (Laupheim, Germany). Human recombinant IL-12 (rIL-12) and rIL-15 were purchased from R&D Systems (Abingdon, UK) and rIL-2 from Chiron Corp (Emeryville, CA). The cytokine concentrations used were as follows, unless otherwise indicated: IFN-α (100 IU/mL), IL-2 (100 IU/mL), IL-12 (5 ng/mL), and IL-15 (5 ng/mL).

RNA isolation and Northern blot analysis. T cells were treated with different cytokines and cells were harvested 3 hours after stimulation. Total cellular RNA was isolated by guanidium isothiocyanate lysis followed by centrifugation through CsCl cushion.[27,28] Total cellular RNA was quantitated photometrically and samples containing equal amounts of RNA (20 μg) were size fractionated on a 1.0% formaldehyde-agarose gel, transferred to a nylon membrane (Hybond; Amersham, Buckinghamshire, UK), and hybridized with the cDNA probes encoding human *IL-2Rα*, *c-myc*, and *pim-1*. EtBr staining of rRNA bands was used to ensure equal RNA loading. The probes were labeled with [α-^{32}P] dCTP (3,000 Ci/mmol; Amersham) using a random primed DNA labeling kit (Boehringer Mannheim, Mannheim, Germany). The membranes were hybridized under conditions of high stringency (50% formamide, 5× Denhardt's solution, 5× SSPE, and 0.5% sodium dodecyl sulfate [SDS]). The membranes were washed twice at room temperature and once at 60°C in 1× SSC/0.1% SDS for 30 minutes each time. The membranes were exposed to Kodak AR X-Omat films (Eastman Kodak, Rochester, NY) at −70°C using intensifying screen.

Electrophoretic mobility shift assay (EMSA). Nuclear extracts[29] and nuclear protein/DNA binding reactions[30] were performed as described previously. *IFP 53* GAS (5′-GATCAATCACCCAGATTCTCAGAAA-CACTT-3′), *IRF-1* GAS (5′-AGCTTCAGCCTGATTTCCCCGAAAT-GACGGA-3′), *pim-1* GAS (5′-ACACACATCCCTTCCCAGAAAT-CAGGATTC-3′), and *IL-2Rα* GAS-c/GAS-n (5′-TTTCTTCTA-GGAAGTACCAAACATTTCTGATAATAGAA-3′) oligonucleotides were synthesized with an IBI oligonucleotide synthesizer (Foster City, CA) and purified on polyacrylamide gel electrophoresis (PAGE) in the presence of 8 mol/L urea. The probes were labeled by T4 polynucleotide kinase. The binding reaction was performed at room temperature for 30 minutes. Samples were analyzed by elecrophoresis on 6% nondenaturing low-ionic strength polyacrylamide gels in 0.25× TBE. The gels were dried and visualized by autoradiography. Antibodies used in supershift experiments were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The following antibodies were used: anti-STAT1 (sc-345X), anti-STAT2 (sc-839X), anti-STAT3 (sc-482X), anti-STAT4 (sc-486X), anti-STAT5b (sc-835X; recognizes both STAT5a and STAT5b), and anti-STAT6 (sc-621X). In supershift experiments, antibod-

ies (1/20 dilution) were incubated with nuclear extracts for 1 hour on ice.

Immunoprecipitation, gel electrophoresis, and Western blotting. T cells were stimulated with different cytokines for 15 minutes, washed once with phosphate-buffered saline (PBS), and lysed in immunoprecipitation buffer (50 mmol/L Tris, pH 7.4, containing 150 mmol/L NaCl, 5 mmol/L EDTA, and 1% Triton X-100) on ice for 15 minutes. Cell lysates were cleared by microfuge centrifugation and immunoprecipitated with anti-STAT1 (Santa Cruz), anti-STAT3 (Santa Cruz), anti-STAT4 (Santa Cruz), anti-STAT5a (71-2400; ZYMED, San Francisco, CA), or anti-STAT5b (71-2500; ZYMED) antibodies.

The proteins were separated on 10% SDS-PAGE using the Laemmli buffer system[31] and transferred electrophoretically onto Immobilon membranes (Millipore, Bedford, MA). Biotinylated antihuman IL-2Rα polyclonal antibody (0.2 μg/mL; BAF223; R&D Systems) was allowed to bind in PBS containing 3% bovine serum albumin (BSA) for 1 hour at room temperature, followed by peroxidase-conjugated streptavidin (1/2,000 dilution; 016-030-084; Jackson ImmunoResearch Laboratories, Inc, West Grove, PA) for 1 hour at room temperature. Primary antiphosphotyrosine antibody (sc-7020; 1/1,000 dilution; Santa Cruz) was allowed to bind in PBS containing 3% BSA for 1 hour at room temperature, followed by secondary antibody binding with Biotin-SP–conjugated goat antimouse IgG (115-066-072; 1/10,000 dilution; Jackson) for 1 hour at room temperature. After this, peroxidase-conjugated streptavidin (Jackson) was allowed to bind for 1 hour at room temperature. The bands were visualized by the ECL chemiluminescence system (Amersham). The membranes were reprobed with anti-STAT1 (Santa Cruz), anti-STAT3 (Santa Cruz), anti-STAT4 (Santa Cruz), anti-STAT5a (ZYMED), or anti-STAT5b (ZYMED) antibodies in PBS containing 5% nonfat milk for 2 hours at room temperature, followed by secondary antibody binding with peroxidase-conjugated goat antirabbit IgG (Bio-Rad, Richmond, CA) for 1 hour at room temperature and visualized by the ECL chemiluminescence system (Amersham).

T-cell proliferation assay. Anti-CD3–activated T cells were removed from IL-2–containing media before the proliferation assay. Cell cultures with greater than 90% viability were used. A total of 10 × 10^6 cells (10^6 cells/mL) were left untreated or treated with IFN-α for 24 hours. The cells were then washed twice with PBS, counted, and resuspended into IFN-free RPMI. Fifty microliters of cell suspension (50,000 cells) was seeded in triplicates into a round-bottom 96-well plate (Greiner, Nürtingen, Germany). IL-2 was added at a final concentration of 0, 10, 30, or 100 IU/mL. After thorough mixing, cells were incubated in 5% CO$_2$ at 37°C for 18 hours. The cells were incubated for another 6 hours in the presence of 1 μCi/well of ^{3}H-labeled thymidine (Amersham). The cells were collected using a harvester (Tomtec Harvester 96 Mach IIIM, Tomtec Inc, Hamden, CT) and counted in a microplate counter (Wallac 1450 Microbeta Liquid Scintillation Counter, Wallac, Turku, Finland). The proliferation index was calculated as follows: index = (IL-2 induced incorporation − background incorporation)/background incorporation.

RESULTS

IFN-α, IL-2, IL-12, and IL-15 enhance IL-2Rα, c-myc, *and* pim-1 *mRNA expression in human T lymphocytes.* IFN-α is an important T-cell regulatory cytokine that, eg, enhances T-cell cytotoxicity[2,3] and stimulates T-cell growth.[32] We therefore studied whether *IL-2Rα*, *c-myc*, and *pim-1,* genes involved in T-cell proliferation previously shown to be induced by IL-2 are also upregulated by IFN-α, IL-12, and IL-15. We used activated T cells to ensure that the cells were maximally responsive to cytokine treatment. T cells were incubated with IFN-α, IL-2, IL-12, or IL-15 or with different combinations of these cytokines. After 3 hours of stimulation, the cells were collected and

total cellular RNA was prepared for Northern blot analysis. IFN-α, IL-2, IL-12, and IL-15 all enhanced *IL-2Rα*, *c-myc*, and *pim-1* mRNA expression (Fig 1A). However, there were certain differences between the cytokines in inducing *IL-2Rα*, *c-myc*, and *pim-1* genes. *IL-2Rα* was induced by IFN-α, IL-2, and IL-15, whereas only a weak induction was seen by IL-12 (Fig 1A). IFN-α, IL-2, IL-12, and IL-15 all induced *c-myc* and *pim-1* gene expression, with IL-12 having the strongest and IL-2 the weakest effect. IL-12 combined with IL-2 or IL-15 most strongly enhanced *IL-2Rα*, *c-myc,* and *pim-1* gene expression. In addition, IFN-α combined with IL-2 or IL-15 had a synergistic effect on the expression of all genes studied (Fig 1A).

Because IFN-α, IL-2, IL-12, and IL-15 upregulated IL-2Rα mRNA expression in activated T cells, we also studied IL-2Rα protein expression by Western blotting. T cells were stimulated for 24 hours with IFN-α, IL-2, IL-12, and IL-15, after which cells were collected and lysates were prepared for Western blot analysis. As shown in Fig 1B, IL-2Rα was expressed at basal level in activated T cells. In accordance with mRNA data, IL-15

was the strongest and IL-12 the weakest inducer of IL-2Rα protein expression. Also, IFN-α and IL-2 clearly upregulated IL-2Rα protein expression (Fig 1B).

Because IFN-α was able to turn on genes associated with T-cell proliferation, we wanted to study the dose-dependent effect of IFN-α and IFN-β on *IL-2Rα*, *c-myc,* and *pim-1* gene expression. Therefore, T cells were treated with different concentrations of IFN-α or IFN-β. Very low doses (1 IU/mL) of IFN-α and IFN-β were able to induce *IL-2Rα*, *c-myc*, and *pim-1* mRNA expression (Fig 2), suggesting that the induction takes place with physiologically relevant IFN concentrations. High expression levels of these genes were detected with 10 IU/mL of both IFN-α and IFN-β.

IFN-α priming enhances IL-2–induced T-cell proliferation. Because IFN-α was able to enhance IL-2Rα gene expression, we studied whether IFN-α pretreatment would sensitize T cells to IL-2–induced cell proliferation. The cells were left untreated or pretreated with IFN-α for 24 hours and restimulated with IL-2, and the T-cell proliferation was analyzed by ^{3}H-labeled thymidine incorporation assay. Proliferation indexes were clearly


Fig 1. (A) Induction of *IL-2Rα*, *c-myc*, and *pim-1* gene expression by IFN-α, IL-2, IL-12, and IL-15 in human T lymphocytes. T cells were stimulated with different cytokines for 3 hours, the cells were collected, and the total cellular RNA was isolated. RNA samples (20 μg) were size-fractionated on agarose gels, transferred to nylon membranes, and hybridized with specific *IL-2Rα, c-myc*, and *pim-1* cDNA probes. EtBr-stained gel is shown to verify equal RNA loading. The result shown is from one experiment but is representative of three individual experiments. (B) Induction of IL-2Rα protein expression by IFN-α, IL-2, IL-12, and IL-15. T cells were stimulated with different cytokines for 24 hours, and cell lysates were prepared. Proteins were separated on 10% SDS-PAGE, transferred to membranes, and immunoblotted with anti–IL-2Rα antibody.

higher in IFN-α–primed cells compared with unprimed ones. This phenomenon was observed with all IL-2 concentrations tested (Fig 3).

Cytokine-induced STAT DNA-binding to the IL-2Rα GAS-c/ GAS-n element. Many cytokines use the Jak/STAT pathway in their signaling and activate genes via GAS elements.[10,33] Recently, an essential upstream IL-2 response element of the *IL-2Rα* gene was characterized. This region contains a consensus and a nonconsensus GAS motif, both of which are required for IL-2–induced *IL-2Rα* gene expression.[34,35] To characterize the proteins capable of binding to the GAS-c/GAS-n element (−3778 to −3740) of the *IL-2Rα* gene, we stimulated T cells with different cytokines, prepared nuclear extracts, and performed EMSA. EMSAs with the GAS-c/GAS-n oligonucleotide showed the induction of one major complex in response to IFN-α, IL-2, IL-12, and IL-15 stimulation (Fig 4A). However, the mobility of IL-2– and IL-15–induced complexes differed from the ones induced by IFN-α or IL-12, suggesting that these

cytokines activate a different range of STAT proteins. The intensity of the IFN-α–induced complex was clearly the strongest. This complex was formed already at 0.5 hours after IFN-α stimulation, and it was detectable at 1 hour after stimulation but disappeared thereafter. Similarly, IL-2–, IL-12–, and IL-15–induced complexes were detectable only at 0.5 hours and 1 hour after stimulation. Next, we identified the proteins within these complexes using specific anti-STAT antibodies in supershift experiments. Antibodies against STAT1 almost completely abolished IFN-α–induced DNA binding to GAS-c/GAS-n. Surprisingly, the addition of anti-STAT3 and anti-STAT4 antibodies resulted in a clearly detectable supershift (Fig 4B). The data suggest that IFN-α–induced complexes consist of at least STAT1, STAT3, and STAT4 proteins. IL-12–induced DNA binding complex reacted only with anti-STAT4 antibodies (Fig 4C). As expected, IL-2 and IL-15 both induced STAT5 DNA binding to GAS-c/GAS-n as detected by supershift experiments (Fig 4B and C).


Fig 2. Dose-dependent activation of *IL-2Rα*, *c-myc*, and *pim-1* gene expression by type I IFNs. T cells were stimulated with different doses of IFN-α or IFN-β for 3 hours, the cells were collected, and total cellular RNA was isolated. RNA samples (20 μg) were size-fractionated on agarose gels, transferred to nylon membranes, and hybridized with *IL-2Rα*, *c-myc*, and *pim-1* cDNA probes. EtBr-stained gel is shown to verify equal RNA loading.

Fig 3. Effect of IFN-α pretreatment on IL-2–induced T-cell proliferation. T lymphocytes were activated with anti-CD3-antibodies and expanded in the presence of IL-2, after which IL-2–containing medium was removed. The cells were then left untreated or treated with 100 IU/mL of IFN-α for 24 hours. The cells were collected, and an equal number of (□) untreated or (■) IFN-α–primed T cells was applied in microtiter plates. Different doses of IL-2 were added for 18 hours, followed by further incubation of 6 hours in the presence of 1 μCi/well of ^{3}H-labeled thymidine. After harvesting the cells, the proliferation index was determined as described in Materials and Methods. The mean proliferation index (±SD) of six individual donors is shown.

IFN-α induces STAT1, STAT3, and STAT4 DNA binding to IRF-1 *and* pim-1 *GAS elements.* Analysis of *pim-1* gene promoter has shown a functional GAS element that binds STAT1 homodimer in response to IFN-γ stimulation.[36] We studied STAT binding to *pim-1* GAS in T lymphocytes in response to cytokine stimulation. EMSA indicated that several STAT complexes were able to bind to *pim-1* GAS element (−934 to −905) in response to IFN-α stimulation (Fig 5A). These complexes were detectable at 0.5 hours after IFN-α treatment and disappeared within 3 hours. IL-12 induced two different DNA binding complexes when *pim-1* GAS was used as a probe (Fig 5A). Both IL-2 and IL-15 induced three different DNA binding complexes. Supershift experiments with specific anti-STAT antibodies indicated that IFN-α–induced complexes consisted of STAT1, STAT3, and STAT4 (Fig 5B). The lowermost complex induced by IFN-α supershifted with anti-STAT1 antibody only. In addition, complexes that supershifted with anti-STAT1 and/or anti-STAT3 antibodies suggested that STAT1-STAT3 heterodimers and STAT3 homodimers were formed after IFN-α stimulation (Fig 5B). The mobility of IL-12–induced complex was comparable to the uppermost complex seen in IFN-α–treated T cells. These complexes supershifted with anti-STAT4 antibodies, suggesting that IFN-α is also able to induce STAT4 DNA binding. In addition, the uppermost complex was also supershifted with anti-STAT1 antibody (Fig 5B), suggesting that heterodimers consisting of STAT1 and STAT4 are formed in response to IFN-α stimulation.

Because *IRF-1* GAS element binds STATs 1, 3, 4, 5, and 6, albeit with different strengths,[33] we wanted to analyze the T-cell–specific STAT binding to this element. Again, IFN-α

induced the DNA binding of multiple complexes (Fig 6A). IFN-α induced the DNA binding of STAT1, STAT3, and STAT4 to *IRF-1* GAS (Fig 6B). IFN-α–induced STAT3 DNA binding to *IRF-1* GAS was very weak compared with STAT1 or STAT4 DNA binding, probably due to the low affinity of STAT3 to IRF-1 GAS. IL-12 induced two complexes, of which the upper complex supershifted with anti-STAT4 antibody only (data not shown). Both IL-2 and IL-15 stimulation resulted in the formation of only one major DNA binding complex that was detectable at least up to 6 hours (Fig 6A). This complex was supershifted with anti-STAT5 antibody (data not shown).

IFN-α enhances STAT1, STAT3, STAT4, STAT5a, and STAT5b tyrosine phosphorylation in anti-CD3–activated human T lymphocytes. Because IFN-α induced STAT1, STAT3, and STAT4 DNA binding to GAS elements, we also analyzed the tyrosine phosphorylation of these proteins. T cells were stimulated with IFN-α or IL-12, STATs were immunoprecipitated with specific antibodies, and their tyrosine phosphorylation was analyzed by antiphosphotyrosine immunoblotting. In unstimulated cells, STAT1 and STAT3 were weakly phosphorylated on tyrosine residues, but IFN-α strongly enhanced STAT1 and STAT3 tyrosine phosphorylation (Fig 7A). Both IFN-α and IL-12 strongly enhanced STAT4 tyrosine phosphorylation (Fig 7A). The blots were stripped of detecting antibody and reprobed for STAT1, STAT3, and STAT4 to confirm equal loading of each lane (lower panel). Because it has previously been shown that IFN-α activates STAT5a in promonocytic U937 and STAT5b in HeLa cells,[37] we wanted to study whether IFN-α is able to induce tyrosine phosphorylation of STAT5 also in human T lymphocytes. T cells were stimulated with IFN-α or IL-2, and STAT5a and STAT5b immunoprecipitates were analyzed by antiphosphotyrosine immunoblotting. IFN-α enhanced tyrosine phosphorylation of both STAT5a and STAT5b (Fig 7B). IL-2 was a much more potent in inducing STAT5a and STAT5b tyrosine phosphorylation than IFN-α. Again, the blots were reblotted with STAT5a and STAT5b antibodies to determine equal loading (lower panel).

Although we observed IFN-α–induced tyrosine phosphorylation of STAT5a and STAT5b, we were not able to detect any clear STAT5 DNA binding to *IL-2Rα, pim-1*, or *IRF-1* GAS elements. To further analyze whether IFN-α is able to activate STAT5 DNA binding in T cells, we performed EMSA with *IFP53* GAS element that is known to bind STAT5 with high affinity.[38] T cells were stimulated with IFN-α and IL-2 for 0.5 hours, and nuclear extracts were prepared and analyzed in EMSA. IFN-α induced both STAT1 and STAT5 DNA binding to *IFP53* GAS, whereas IL-2 was able to induce the DNA binding of STAT5 (Fig 8).

IFN-α priming enhances IL-2–induced STAT1 and STAT5 DNA binding. Because IFN-α priming enhanced IL-2–induced T-cell proliferation (Fig 3), we studied whether IFN-α has any effect on IL-2–induced STAT DNA binding. T cells were left untreated or treated with IFN-α for 24 hours, followed by stimulation with different concentrations of IL-2 (0, 3, 10, or 30 IU/mL) for 30 minutes. In unprimed T cells, IL-2 induced one major and one minor *IRF-1* GAS binding complex. In IFN-α–primed, IL-2–stimulated cells, *IRF-1* GAS DNA binding was markedly enhanced. The upper complex supershifted with anti-STAT5 antibody and the lower complex with anti-

Fig 4. **(A)** STAT DNA binding to the *IL-2Rα* GAS-c/GAS-n in response to cytokine stimulation. T cells were stimulated with IFN-α, IL-2, IL-12, or IL-15 as indicated; nuclear extracts were prepared from the cells; and the STAT DNA binding was analyzed by EMSA. **(B)** STAT DNA binding to the *IL-2Rα* GAS-c/GAS-n in response to IFN-α and IL-2. T cells were stimulated with IFN-α or IL-2 for 30 minutes, after which nuclear extracts were prepared. Nuclear extracts were incubated for 1 hour on ice with STAT antibodies indicated, followed by binding to ^{32}P-labeled *IL-2Rα* GAS-c/GAS-n probe. **(C)** STAT DNA binding to the *IL-2Rα* GAS-c/GAS-n in response to IL-12 and IL-15. T cells were stimulated with IL-2 or IL-15 for 30 minutes, and nuclear extracts were prepared and incubated for 1 hour on ice with different anti-STAT antibodies followed by binding to ^{32}P-labeled *IL-2Rα* GAS-c/GAS-n probe. The results are representative of three separate experiments.

STAT1 antibody (Fig 9). The data suggest that in T cells IL-2 can activate STAT1 and that the IFN-α pretreatment strongly enhances IL-2–induced STAT1 (and STAT5) DNA binding (Fig 9). Enhanced STAT1 and STAT5 complex formation in IFN-α–primed T cells in response to IL-2 stimulation was also detected when *pim-1* GAS was used as a probe in EMSA (data not shown). In contrast, IFN-α did not enhance IL-2–induced STAT5 DNA binding to IL-2Rα GAS-c/GAS-n (data not shown).

DISCUSSION

The gene knock-out studies have shown that a functional IFN-α/β system is essential for the clearance of viral infection.[4,39,40] It is also well accepted that IFN-α can directly inhibit proliferation of normal and tumor cells in vitro and in vivo.[41] However, there is some evidence that IFN-α would enhance T-cell growth. Tough et al[32] have shown that IFN-α–stimulated CD8$^+$ cells proliferate and survive in vivo for longer periods of

time than their unstimulated counterparts. In the present study, we demonstrate that IFN-α priming can augment IL-2–induced human T-cell proliferation in vitro, and this phenomenon was associated with the induction of *IL-2Rα*, *c-myc*, and *pim-1* gene expression. Especially, IFN-α–induced upregulation of *IL-2Rα* expression could directly contribute to enhanced responsiveness of T cells to IL-2. Enhanced *pim-1* gene expression may also contribute to increased T-cell survival. There is evidence that overexpression of *pim-1* can accelerate lymphoproliferation by inhibiting apoptosis.[24,25] Recent results from studies on cytokine-mediated signaling suggest that pim-1 expression correlates with the viability, but not with the proliferation potential of the cells.[42,43]

Not only IFN-α and IL-2, but also IL-12 and IL-15 as well induced the expression of the *IL-2Rα* gene in anti-CD3–activated T lymphocytes. Induction of *IL-2Rα* gene expression by IL-15 was expected, because IL-15 also activates STAT5 and uses β and γ chains of the IL-2 receptor during downstream

Fig 5. **(A) Multiple STAT complexes bind to the *pim-1* GAS element in response to cytokine stimulation.** T cells were stimulated with IFN-α, IL-2, IL-12, or IL-15 for the indicated times, and nuclear extracts were prepared from the cells. The extracts were incubated with ^{32}P-labeled *pim-1* GAS probe, and the STAT DNA binding was analyzed by EMSA. **(B) IFN-α induced STAT1, STAT3, and STAT4 DNA binding to *pim-1* GAS.** T cells were stimulated with IFN-α for 30 minutes, and nuclear extracts were prepared. The extracts were incubated for 1 hour on ice with anti-STAT antibodies, followed by binding to ^{32}P-labeled *pim-1* GAS probe. Comparable data were obtained in three independent experiments, each consisting of pooled T cells from two different donors.

signaling.[11] However, the finding that IFN-α and IL-12 induced the upregulation of *IL-2Rα* gene expression was more surprising. An IL-2–responsive element in the IL-2Rα gene promoter has recently been characterized.[34,35] This element binds at least STAT5, Elf-1, HMG-I(Y), and GATA family transcription factors. The STAT5 binding site consists of two adjacent GAS elements, a consensus GAS (GAS-c) and a nonconsensus one (GAS-n), which are well-conserved in human and mouse promoters. Single GAS elements of *IL-2Rα* promoter appear to function only as low-affinity STAT5 binding sites and therefore both of these elements are required for IL-2–induced STAT5 binding.[44] Previously, cooperative binding of STAT complexes to weak STAT binding sites has been observed, eg, in the first intron of *IFN-γ*[45] gene and in the promoter of *mig* chemokine

gene.[46] In our experiments, by using nuclear extracts from cytokine-stimulated T cells, we were able to detect not only IL-2– and IL-15–induced STAT5 binding, but also IL-12–induced STAT4 binding to the *IL-2Rα* GAS-c/GAS-n element. More interestingly, the IFN-α–induced complexes consisted of STAT1, STAT3, and STAT4 proteins, suggesting similar cooperative STAT binding mechanisms as described for the other genes mentioned above.[45,46]

The expression of *c-myc* and *pim-1* genes was induced in human T cells by IL-2, which is the primary growth factor of mature T cells. We observed that both IFN-α and IL-12 were able to upregulate the expression of *c-myc* and *pim-1* genes in anti-CD3–activated T lymphocytes. *pim-1* gene promoter contains a functional GAS element.[36] It is also presumable that

Fig 6. (A) STAT binding to the *IRF-1* GAS by IFN-α, IL-2, IL-12, or IL-15. T cells were stimulated with IFN-α, IL-2, IL-12, or IL-15 for the times indicated, and nuclear extracts were prepared. The extracts were incubated with ^{32}P-labeled *IRF-1* GAS probe, and the DNA binding activity was analyzed by EMSA. (B) IFN-α–induced STAT1, STAT3, and STAT4 DNA binding to *IRF-1* GAS. T cells were stimulated with IFN-α for 30 minutes, and nuclear extracts were prepared and incubated for 1 hour on ice with anti-STAT antibodies, followed by binding to ^{32}P-labeled *IRF-1* GAS. The experiment was repeated three times with similar results.

IFN-α– and IL-12–activated STAT proteins are involved in the upregulation of *pim-1* gene expression. Indeed, we were able to demonstrate that IFN-α induced STAT1, STAT3, and STAT4 DNA binding to *pim-1* GAS. Similarly, IL-12 induced STAT4 binding to *pim-1* GAS. In addition, it has been shown that IL-12 upregulates *c-myc* gene expression in NK and T cells.[47] It is also known that Jak3 tyrosine kinase is essential for IL-2–induced expression of *c-myc* gene,[48] but there is little information about downstream signal transducing molecules and no evidence of STAT protein involvement. Further analyses of the molecular mechanisms of IFN-α–, IL-2–, and IL-12–induced *c-myc* gene expression are clearly needed.

Previously, IFN-α was observed to be able to specifically activate IFN-stimulated gene factor complex (STAT1, STAT2, and p48 heterotrimer).[49] Our results suggest that IFN-α can also induce the DNA binding of STAT3, STAT4, and STAT5 to the specific GAS elements in human T lymphocytes. IFN-α–induced STAT3 activation takes place in certain cell types,[50,51] and this has been suggested to be due to a direct phosphotyrosine-dependent interaction between IFNAR-1 and the SH2 domain of STAT3.[52] Whether similar interactions between STAT4 or STAT5 with the type I IFN receptor exist remains to be studied. Previously, it was demonstrated that both IL-12 and IFN-α were able to activate DNA binding of STAT4 to *FcγRI* GAS in T lymphocytes.[53] In the present study, we clearly demonstrate that in our T-cell system both IFN-α and IL-12 can induce STAT4 tyrosine phosphorylation and subsequent binding of STAT4 to *IRF-1* and *pim-1* GAS elements. This is consistent with the Northern blot data that demonstrated that *pim-1* (Fig 1) as well as *IRF-1* (data not shown) genes were upregulated by IFN-α and IL-12.

We also observed that IFN-α enhanced tyrosine phosphoryla-

Fig 7. (A) IFN-α induces tyrosine phosphorylation of STAT1 and STAT4 in human T lymphocytes. T cells were treated with IFN-α or IL-12 for 15 minutes, and T-cell lysates were prepared and immunoprecipitated with anti-STAT1, anti-STAT3, or anti-STAT4 antibodies. Proteins were separated on 10% SDS-PAGE, transferred to membranes, and immunoblotted with antiphosphotyrosine antibody. The membranes were stripped and reblotted with anti-STAT antibodies. (B) IFN-α induces tyrosine phosphorylation of STAT5a and STAT5b. T cells were treated with IFN-α or IL-2 for 15 minutes and T-cell lysates were prepared. The lysates were immunoprecipitated with anti-STAT5a or anti-STAT5b antibodies, followed by immunoblotting with antiphosphotyrosine antibody. Membranes were then stripped and reblotted with anti-STAT antibodies, as indicated.

tion of STAT5a and STAT5b in T cells. It was previously shown that IFN-α selectively enhances tyrosine phosphorylation and DNA binding of STAT5a and STAT5b in U937 cells and in HeLa cells, respectively, although both cell types are able to

express STAT5a and STAT5b.[37] This suggests that cell-type–specific mechanisms regulate IFN-α–induced activation of different STAT5 isoforms. Our results show that, in human T cells, IFN-α induces the tyrosine phosphorylation of both


Fig 8. IFN-α–induced STAT5 DNA binding to the *IFP53* GAS element. T cells were stimulated with IFN-α or IL-2 for 30 minutes, and nuclear extracts were prepared and incubated with anti-STAT1 or anti-STAT5 antibodies for 1 hour on ice, followed by EMSA with ^{32}P-labeled *IFP53* GAS probe.

Fig 9. IFN-α enhances IL-2–induced STAT1 and STAT5 binding to the *IRF-1* GAS. T cells were left untreated or treated with IFN-α (100 IU/mL) for 24 hours. The cells were washed and resuspended in fresh medium, and different concentrations of IL-2 (0, 3, 10, or 30 IU/mL) were added. After 30 minutes of incubation, nuclear extracts were prepared and analyzed in EMSA with *IRF-1* GAS probe. The experiment was repeated three times with similar results.

STAT5a and STAT5b. IFN-α–induced STAT5a and STAT5b tyrosine phosphorylation was much weaker compared with IL-2 induction, and no clear IFN-α–induced STAT5 DNA binding to *IRF-1, pim-1*, or *IL-2Rα* GAS elements was detected. However, IFN-α induced STAT5 DNA binding to *IFP53* GAS element, which is known to bind STAT5 with high affinity.[38] This may suggest that IFN-α–induced STAT5 activation has physiological significance in the activation of genes that contain high-affinity STAT5 binding sites.

Because IFN-α was able to enhance *IL-2Rα* gene expression and T-cell proliferation, we studied the role of IFN-α in IL-2–induced STAT activation. Pretreatment of T cells with IFN-α resulted in a twofold to threefold increase in IL-2–induced STAT5 DNA binding, which may contribute to the enhanced T-cell proliferation. In IFN-α–pretreated T cells, IL-2–induced STAT1 DNA binding was strongly enhanced (Fig 9). This could be due to the upregulation of intracellular STAT1 levels or, alternatively, to enhanced IL-2–induced signaling in IFN-α pretreated cells. The former possibility may be the more likely one, because IFN-α strongly enhances STAT1, STAT2, and p48 mRNA and protein expression in peripheral blood mononuclear cells and in human macrophages[54] as well as in T lymphocytes (data not shown). However, STAT1 was expressed in relatively high levels in T cells and it is possible that other mechanisms, such as STAT1 tyrosine or serine/threonine phosphorylation by IFN-α, may also explain enhanced IL-2–induced STAT1 DNA binding in IFN-α–primed T cells.

IFN-α was first described as a substance inhibiting virus growth in infected cells.[55] Thereafter, much of the research work focused on the antiviral and antiproliferative properties of IFN-α, and its role as an important T-cell regulatory molecule was neglected.[2] In the present study, we provide evidence that IFN-α/β is able to activate the expression of *IL-2Rα, c-myc,* and *pim-1* genes that are involved in T-cell proliferation or survival. Pretreatment of activated T cells with IFN-α also enhanced IL-2–induced T-cell proliferation, suggesting that, in T cells, IFN-α is rather growth stimulatory than inhibitory. In addition,

in T cells, IFN-α was able to activate STAT4 and STAT5, the signaling molecules used by IL-12 and IL-2, respectively, which further emphasizes the role of IFN-α/β as important molecules in T-cell biology.

ACKNOWLEDGMENT

REFERENCES

1. Sen GC, Ransohoff RM: Interferon-induced antiviral actions and their regulation. Adv Virus Res 42:57, 1993
2. Belardelli F, Gresser, I: The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol Today 17:369, 1996
3. Herbermann RB: Effect of α-interferons on immune function. Semin Oncol 24:S9, 1997
4. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M: Functional role of type I and II interferons in antiviral response. Science 264:1918, 1994
5. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia F: Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185:825, 1997
6. Manetti R, Annunziato F, Tomasevic L, Gianno V, Parronchi P, Romagnani S, Maggi E: Polyinosinic acid: Polycytidylic acid promotes T helper type 1-specific immune responses by stimulating macrophage production of interferon-alpha and interleukin-12. Eur J Immunol 25:2656, 1995
7. Sareneva T, Matikainen S, Kurimoto M, Julkunen I: Influenza A virus-induced IFN-α/β and IL-18 synergistically enhance IFN-γ gene expression in human T cells. J Immunol 160:6032, 1998
8. Hou J, Schindler U, Henzel WJ, Wong SC, McKnight SL: Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity 2:321, 1995
9. Taniguchi T: Cytokine signaling through nonreceptor protein tyrosine kinases. Science 268:251, 1995
10. O'Shea JJ: Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet? Immunity 7:1, 1997

11. Waldmann T, Tagaya Y, Bamford R: Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 16:205, 1998

12. Fujii H, Nakagawa Y, Schindler U, Kawahara A, Mori H, Gouilleux F, Groner B, Ihle JN, Minami Y, Miyazaki T, Taniguchi T: Activation of STAT5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor β chain but is not essential for proliferative signal transmission. Proc Natl Acad Sci USA 92:5482, 1995

13. Friedmann MC, Migone TS, Russell SM, Leonard WJ: Different interleukin 2 receptor β-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin-2-induced proliferation. Proc Natl Acad Sci USA 93:2077, 1996

14. Nakajima H, Liu X-W, Wynshaw-Boris A, Rosenthal LA, Imada K, Finbloom DS, Hennighausen L, Leonard WJ: An indirect effect of STAT5a in IL-2-induced proliferation: A critical role for STAT5a in IL-2-mediated IL-2 receptor α chain induction. Immunity 7:691, 1997

15. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K, Nakamura M, Takeshita T: The interleukin-2 receptor γ chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14:179, 1996

16. Sharfe N, Dadi HK, Shahar M, Roifman CM: Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc Natl Acad Sci USA 94:3168, 1997

17. Dautry FD, Weil D, Yu J, Dautry-Varsat A: Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem 263:17615, 1988

18. Koskinen PJ, Alitalo K: Role of myc amplification and overexpression in cell growth, differentiation and death. Semin Cancer Biol 4:3, 1993

19. Meeker TC, Nagarajan L, ar-Rushdi A, Rovera G, Huebner K, Croce CM: Characterization of the human PIM-1 gene: A putative oncogene coding for a tissue specific member of the protein kinase family. Oncogene Res 1:87, 1987

20. Amson R, Sigaux F, Przedporski S, Flandrin G, Givol D, Telerman A: The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 86:8857, 1989

21. Möröy T, Verbeek S, Ma S, Achacoso P, Berns A, Alt F: Em N- and Em L-myc cooperate with Em-pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Oncogene 6:1941, 1991

22. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal GP, Berns A: Mice bearing the Em-myc and Em-pim-1 transgene develop pre-B-cell leukemia prenatally. Mol Cell Biol 11:1176, 1991

23. Acton D, Domen J, Jacobs H, Vlaar M, Korsmeyer S, Berns A: Collaboration of PIM-1 and BCL-2 in lymphomagenesis. Curr Top Microbiol Immunol 182:293, 1992

24. Domen J, van der Lugt NM, Acton D, Laird PW, Linders K, Berns A: Pim-1 levels determine the size of early B lymphoid compartments in bone marrow. J Exp Med 178:1665, 1991

25. Möröy TA, Grzeschiczek A, Petzold S, Hartmann K-U: Expression of a *pim-1* transgene accelerates lymphoproliferation and inhibits apoptosis in *lpr/lpr* mice. Proc Natl Acad Sci USA 90:10734, 1993

26. Lilly M, Kraft A: Enforced expression of the M_r 33,000 pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res 57:5348, 1997

27. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294, 1979

28. Glisin V, Crkvenjankov R, Byus C: Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry 13:2633, 1974

29. Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limited numbers of mammalian cells. Nucleic Acids Res 19:2499, 1991

30. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I: Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 88:114, 1996

31. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680, 1970

32. Tough DF, Borrow P, Sprent J: Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272:1947, 1996

33. Decker T, Kovarik P, Meinke A: GAS elements: A few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 17:121, 1997

34. John S, Robbins CM, Leonard WJ: An IL-2 response element in the human IL-2 receptor α chain promoter is a composite element that binds STAT5, Elf-1, HMG-I(Y) and a GATA family protein. EMBO J 15:5627, 1996

35. Lecine P, Algarte M, Rameil P, Beadling C, Bucher P, Nabholz M, Imbert J: Elf-1 and STAT5 bind to a critical element in a new enhancer of the human interleukin-2 receptor α gene. Mol Cell Biol 16:6829, 1996

36. Yip-Schneider MT, Horie M, Broxmeyer HE: Transcriptional induction of pim-1 protein kinase gene expression by interferon-gamma and posttranscriptional effects on costimulation with steel factor. Blood 85:3494, 1995

37. Meinke A, Barahmand-Pour F, Wöhrl S, Stoiber D, Decker T: Activation of different STAT5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol 16:6937, 1996

38. Eilers A, Baccarini M, Horn F, Hipskind RA, Schindler C, Decker T: A factor induced by differentiation signals in cells of the macrophage lineage binds to the gamma interferon activation site. Mol Cell Biol 14:1364, 1994

39. Durbin, JE, Hackenmiller R, Simon MC, Levy DE: Targeted disruption of the mouse STAT1 gene results in compromised innate immunity to viral disease. Cell 84:443, 1996

40. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD: Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431, 1996

41. Cirelli R, Tyring SK: Major therapeutic uses of interferons. Clin Immunother 3:27, 1995

42. Joneja B, Wojchowski DM: Mitogenic signaling and inhibition of apoptosis via erythropoietin receptor box-1 domain. J Biol Chem 272:11176, 1997

43. Sakai I, Kraft AS: The kinase domain of Jak2 mediates induction of Bcl-2 and delays cell death in hematopoietic cells. J Biol Chem 272:12350, 1997

44. Meyer WK-H, Reichenbach P, Schindler U, Soldaini E, Nabholz M: Interaction of STAT5 dimers on two low affinity sites mediates interleukin 2 (IL-2) stimulation of IL-2 receptor α gene expression. J Biol Chem 272:31821, 1997

45. Xu X, Sun Y-L, Hoey T: Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 273:794, 1996

46. Vinkemeir U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell JE Jr: DNA binding of *in vitro* activated STAT1α, STAT1β, and truncated STAT1: Interaction between NH_2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 15:5616, 1996

47. Azzoni A, Kanakaraj P, Zatsepina O, Perussia B: IL-12-induced activation of NK and T cells occurs in the absence of immediate-early activation of gene expression. J Immunol 157:3235, 1997

48. Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu Z-J, Oishi I, Silvennoinen O, Witthuhn BA, Ihle JN, Taniguchi T: Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266:1045, 1994

49. Schindler C, Darnell JE Jr: Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 64:621, 1995

50. Harroch S, Revel M, Chebath J: Interleukin-6 signaling via transcription factors binding palindromic enhancers of different genes. J Biol Chem 269:26191, 1994

51. Raz J, Durbin E, Levy DE: Acute phase response factor and additional members of the interferon-stimulated gene factor 3 family integrate diverse signals from cytokines, interferons, and growth factors. J Biol Chem 269:24391, 1994

52. Yang C-H, Shi W, Basu L, Murti A, Constantinescu SN, Blatt L, Croze E, Mullersman JE, Pfeffer LM: Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem 271:8057, 1996

53. Cho SS, Bacon CM, Sudarshan C, Rees RC, Finbloom D, Pine R, O'Shea JJ: Activation of STAT4 by IL-12 and IFN-α: Evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 157:4781, 1996

54. Lehtonen A, Matikainen S, Julkunen I: Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol 159:794, 1997

55. Isaacs A, Lindenmann J: Virus interference I. The interferon. Proc Soc Lond 147:258, 1957

Virus-associated hemophagocytic syndrome. A healthy 18-year-old senior high school student presented with several weeks of myalgias, fevers, and sore throat. She subsequently developed pancytopenia and hepatic dysfunction. A thorough evaluation was unrevealing except for a positive monospot and Epstein-Barr virus (EBV) VCA-IgG with a negative EBV VCA-IgG and EBNA (both became positive several weeks later). A diagnosis of acute EBV infection was made. Over the next 3 weeks she had a waxing and waning course but finally required hospital admission due to worsening pancytopenia (WBC, 300/μL; hematocrit, 16.2%; and platelet count, 44,000/μL) and hepatic dysfunction (ALT, 636 U/L; AST, 608 U/L; LDH, 2,788 U/L; direct bilirubin, 32.2 mg/dL; and prothrombin time, 16 seconds). Her physical exam was notable for a fever (39.5°C), a diffuse fine scaly rash, severe icterus, no adenopathy, a liver span of 14 cm in the midclavicular line, and a spleen tip palpable 2 cm below the costal margin. Biopsy of her bone marrow showed overall hypocellularity with multiple nests of RBCs (arrows in figure on left; original magnification ×100). These nests of RBCs, as seen in the bone marrow aspirate (figure on right; original magnification ×2,500), represent histiocytes with engulfed erythrocytes characteristic of hemophagocytosis. Despite intense immunosuppressive therapy (including steroids, cyclosporin A, IVIG, and ATG), she developed respiratory failure, gastrointestinal bleeding, renal failure (requiring dialysis), cardiac dysfunction (with global hypokinesis), and pancreatitis. She finally succumbed to an intracranial hemorrhage. Virus-associated hemophagocytic syndrome is typically associated with acute EBV infection. It is characterized by constitutional symptoms, including fever, rash, lymphadenopathy, and hepatosplenomegaly. Therapy is directed at the immune dysregulation and is often ineffective, as in this unfortunate case. (Courtesy of Lindsey Baden, MD, and Frank Evangelista, MD, Beth Israel Deaconess Medical Center, Departments of Medicine and Pathology, 330 Brookline Ave, SL-435, Boston, MA 02215.)